Pliant Therapeutics, Inc.
NASDAQ:PLRXBiotechnology
-$0.04 today
- Market cap
- $50.14M
- Beta
- 1.21
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.83
Volume 0.15M
Average 0.49M
PLRX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Pliant Therapeutics, Inc.NASDAQ: PLRX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $8.19M fell 47.2% year over year, behind the -32.7% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 2.5% from the prior quarter. Over 3 fiscal years it compounded at +5.7% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $23.21M (-50.8%) for the fiscal year ending Dec 2026, a slowdown from the -20.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $8.19M+2.5% QoQ
- Last fiscal yearDec 2025
- $47.22M-20.0% YoY
- LTMMar 2026
- $39.91M-32.7% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 47.22M USD
- Year-over-year change
- -20.0%
- 4-year CAGR
- +14.4%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 47.22M | -20.0% |
| FY2024 | 2024-12-31 | 59.06M | +1.9% |
| FY2023 | 2023-12-31 | 57.93M | +45.0% |
| FY2022 | 2022-12-31 | 39.95M | +45.0% |
| FY2021 | 2021-12-31 | 27.56M | — |
Selling, General & Admin vs competitors
How PLRX compares with its peers on the latest reported figures
- PLRX's LTM Mar 2026 selling, general & admin of $39.91M is the 2nd highest of the 10 companies compared; the peer median is $24.75M.
- Its year-over-year change of -32.7% is the 6th highest of 9, against a peer median of -27.9%.
- Over three fiscal years its annual growth of +5.7% compares with a peer median of -9.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.7B | +73001.9% | +33.2% | 84342.9% | |
| LTM Mar 2026 | $39.91M | -32.7% | +5.7% | — | |
| LTM Mar 2026 | $38.15M | -27.9% | -12.7% | 24.3% | |
| LTM Mar 2026 | $35.33M | -27.9% | -11.7% | 35.5% | |
| LTM Mar 2026 | $34.97M | -57.3% | -11.6% | — | |
| LTM Mar 2026 | $24.75M | -6.4% | -9.4% | 347.5% | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $23.29M | -40.2% | -9.5% | — |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $20.27M | +8.2% | -0.8% | — |
| LTM Mar 2026 | $17.25M | — | +15.2% | — | |
| LTM Mar 2026 | $7.9M | -34.1% | -17.0% | 5897.0% | |
| Peer median (excluding PLRX) | $24.75M | -27.9% | -9.5% | 347.5% | |
Competitors are the stored peer set for PLRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.57M | 9.69M | 1.58M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.7M |
| Gross Profit | 7.57M | 9.69M | 1.58M | 0 | (1.7M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 77.55M | 96.94M | 127.8M | 169.31M | 109.16M |
| Selling, General & Admin | 27.56M | 39.95M | 57.93M | 59.06M | 47.22M |
| Operating Expenses | 105.11M | 136.89M | 185.73M | 228.37M | 148.38M |
| Depreciation & Amortization | 1.54M | 3.68M | 1.84M | 2.13M | 1.7M |
| EBITDA | (95.73M) | (118.85M) | (158.23M) | (205.16M) | (145.09M) |
| EBITDA Margin | -1264.2% | -1227.1% | -10014.4% | — | — |
| Operating Income | (97.54M) | (127.2M) | (184.15M) | (228.37M) | (150.07M) |
| Operating Margin | -1288.1% | -1313.4% | -11654.7% | — | — |
| Interest Income | 272K | 4.67M | 24.08M | 21.09M | 0 |
| Interest Expense | 0 | 791K | 1.27M | 3.02M | 2.56M |
| Other Income / Expenses | 272K | 3.88M | 22.81M | 18.06M | 729K |
| Income Before Tax | (97.26M) | (123.32M) | (161.34M) | (210.3M) | (149.34M) |
| Pre-Tax Margin | -1284.5% | -1273.3% | -10211.1% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (97.26M) | (123.32M) | (161.34M) | (210.3M) | (149.34M) |
| Net Margin | -1284.5% | -1273.3% | -10211.1% | — | — |
| EPS (Basic) | (2.71) | (2.94) | (2.75) | (3.47) | (2.43) |
| EPS (Diluted) | (2.71) | (2.94) | (2.75) | (3.47) | (2.43) |
| Weighted Avg Shares | 35.85M | 42.02M | 58.72M | 60.54M | 61.37M |
| Weighted Avg Shares (Diluted) | 35.85M | 42.02M | 58.72M | 60.54M | 61.37M |
Pliant Therapeutics, Inc.
NASDAQ:PLRX
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.